Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand

Journal of Investigative Dermatology

Volumn 113, Issue 6, 1999, Pages 1028-1032

  Esche, Clemens ^a   Subbotin, Vladimir M ^b   Hunter, Oriana ^a   Peron, Jean Marie ^a   Maliszewski, Charles ^c   Lotze, Michael T ^a   Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

Author keywords

Antigen presenting cell; Cell trafficking; Cytokine; Langerhans cell

Indexed keywords

INTERLEUKIN 12;

ARTICLE; CELL COUNT; CONTROLLED STUDY; DENDRITIC CELL; DERMIS; EPIDERMIS; IMMUNOTHERAPY; LANGERHANS CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SKINFOLD THICKNESS;

EID: 0033384979     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00779.x     Document Type: Article

References (32)

1. Belsito DV, Sanchez MR, Baer RL, Valentine F, Thorbecke J: Reduced Langerhans' cell 1a antigen and ATPase activity in patients with the acquired immunodeficiency syndrome. N Engl J Med 310:1279-1282, 1984
2. Borkowski TA, Letterio JJ, Farr AG, Udey MC: A role for endogenous transforming growth factor β1 in Langerhans cell biology: The skin of β1 null mice is devoid of epidermal Langerhans cells. J Exp Med 184:2417-2422, 1996
3. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261, 1992
4. Chu A, Eisinger M, Lee JS, Takezaki S, Kung PC, Edelson RL: Immunoelectron microscopic identification of Langerhans cells using a new antigenic marker. J Invest Dermatol 78:177-180, 1982
5. Daniels TE, Greenspan D, Greenspan JS, Lennette E, Schiodt M, Petersen V, de Souza Y: Absence of Langerhans cells in oral hairy leukoplakia, an AIDS-associated lesion. J Invest Dermatol 89:178-182, 1987
6. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3 Ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58:380-383, 1998
7. Esche C, Shurin MR, Lotze MT: The use of dendritic cells for cancer vaccination. Curr Op Mol Ther 1:72-81, 1999a
8. Esche C, Shurin MR, Lotze MT: Gene therapy for melanoma. Dermatol Ther 10:74-82, 1999b
9. Esche C, Lokshin A, Shurin GV, et al: Tumor's other immune targets: dendritic cells. J Leukoc Biol 66:336-344, 1999c
10. Esche C, Gambotto A, Satoh Y, et al: CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 29:2148-2155, 1999d
11. Facchetti F, Wolf-Peeters C, de Greef H, Desmet VJ: Langerhans cells in various benign and malignant pigment-cell lesions of the skin. Arch Dermatol Res 276:283-287, 1984
12. Garcia-Plata D, Lessana-Leibowitch M, Palangie A, Gulliemette J, Sedel D, Mendez L, Mozos E: Immunophenotype analysis of dendritic cells and lymphocytes associated with cutaneous malignant melanomas. Invasion Metastasis 15:125-134, 1995
13. Gatter KC, Morris HB, Roach B, Mortimer P, Fleming KA, Mason DY: Langerhans' cells and T cells in human skin tumors: an immunohistological study. Histopathology 8:229-244, 1984
14. Grabbe S, Bruvers S, Gallo RL, Knisely TL, Nazareno R, Granstein R: Tumor antigen presentation by murine epidermal cells. J Immunol 146:3656-3661, 1991
15. Grohmann U, Belladonna ML, Bianchi R, Orabona C, Ayroldi E, Fioretti MC, Puccetti P: IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 9:315-323, 1998
16. Katz SI, Tamaki K, Sachs SH: Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 282:324-326, 1979
17. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625-631, 1997
18. MacKie RM: Initial event in mycosis fungoides of the skin is viral infection of epidermal Langerhans cells. Lancet 2:283-285, 1981
19. Magram J, Connaughton SE, Warrier RR, et al: IL-12 deficient mice are defective in IFNγ production and type 1 cytokine responses. Immunity 4:471-481, 1996
20. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ: Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 184:1953-1962, 1996
21. Morhenn VB: Langerhans cells may trigger the psoriatic disease via production of nitric oxide. Immunol Today 18:433-436, 1997
22. Nestle FO, Filgueira L, Nickoloff BJ, Burg G: Human dermal dendritic cells process and present soluble protein antigens. J Invest Dermatol 110:762-766, 1998
23. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR: FLT3-Ligand administration inhibits liver metastases: Role of NK cells. J Immunol 161:6164-6170, 1998
24. Reid CD, Fryer PR, Clifford C, Kirk A, Tikerpae J, Knight SC: Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 76:1139-1149, 1990
25. Reid CD, Stackpoole A, Meager A, Tikerpae J: Interactions of tumor necrosis factor with granulocyte-macrophage colony stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 149:2681-2688, 1992
26. Shurin MR, Pandharipande PP, Zorina T, et al: FLT3 Ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 179:174-184, 1997a
27. Shurin MR, Esche C, Peron JM, Lotze MT: Anti-tumor activities of Interleukin-12 and mechanisms of action, Chem Immunol 68:153-174, 1997b
28. Shurin MR, Esche C, Lotze MT: FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev 9:37-48, 1998
29. Steinman R, Hoffman L, Pope M: Maturation and migration of cutaneous dendritic cells. J Invest Dermatol 105:2S-7S, 1995
30. Stene MA, Babajanians M, Bhuta S, Cochran AJ: Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol 91:125-128, 1988
31. Taylor RS, Baadsgaard O, Hammerberg C, Cooper KD: Hyperstimulatory CD1a+CD1b+CD36+ Langerhans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dermatitis. J Immunol 147:3794-3802, 1991
32. Toews GB, Bergstresser PR, Streilein JW, Sullivan S: Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 124:445-453, 1980